[{"symbol": "BLTE", "price": 155.11, "beta": -1.461, "volAvg": 212796, "mktCap": 5411941614, "lastDiv": 0, "range": "49-170.245", "changes": 5.5, "companyName": "Belite Bio, Inc", "currency": "USD", "cik": "0001889109", "isin": "US07782B1044", "cusip": "07782B104", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://belitebio.com", "description": "Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.", "ceo": "Yu-Hsin Lin", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "25", "phone": "858-246-6240", "address": "5820 Oberlin Drive", "city": "San Diego", "state": "CA", "zip": "92121", "dcfDiff": 154.0903, "dcf": 1.0197005224049556, "image": "https://images.financialmodelingprep.com/symbol/BLTE.png", "ipoDate": "2022-04-29", "defaultImage": true, "isEtf": false, "isActivelyTrading": true, "isAdr": true, "isFund": false}]